Press release
United States GnRH Agonists and Antagonists Drugs for Endometriosis Market to hit US$ 2,079.94 million by 2031 | Top Companies - TerSera Therapeutics LLC, Takeda Pharmaceutical Company Limited, Cipla, Lupin
GnRH Agonists and Antagonists Drugs for Endometriosis Market
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/gnrh-agonists-and-antagonists-drugs-for-endometriosis-market?kb
United States: Recent Industry Developments
✅ November 2025: Pfizer expanded clinical trials of its oral GnRH antagonist for improved management of endometriosis symptoms.
✅ October 2025: AbbVie received FDA approval for a next-generation GnRH agonist implant targeting long-term endometriosis treatment.
✅ September 2025: Enhanced patient support programs launched to improve adherence to GnRH therapies among women with endometriosis.
GCC: Recent Industry Developments
✅ November 2025: GCC healthcare providers increased adoption of GnRH antagonist therapies with growing awareness of minimally invasive treatment options.
✅ October 2025: Collaborative workshops conducted across GCC countries to train healthcare professionals on GnRH drug administration protocols.
✅ September 2025: Regional pharmaceutical companies expanded distribution networks for GnRH-based drugs to improve patient access.
MENA: Recent Industry Developments
✅ November 2025: Governments in MENA initiated public health campaigns to raise awareness about endometriosis and available GnRH treatments.
✅ October 2025: Local biotech firms partnered with international pharmaceutical companies to enhance production of GnRH antagonists.
✅ September 2025: Hospitals in key MENA markets integrated GnRH therapy protocols into standard endometriosis care pathways.
Major Growing Players:
Bayer AG, Ferring, Abbvie Inc., AstraZeneca, Merck KGaA, Ipsen Pharma, TerSera Therapeutics LLC, Takeda Pharmaceutical Company Limited, Cipla, Lupin
Latest M&A
Medicus Pharma acquired Antev Limited (Sep 2025) for Teverelix, a next-gen GnRH antagonist targeting $6B prostate cancer/AUR market with lower CV risk. Medicus secured $8M non-dilutive financing to advance Teverelix Phase 2. Kissei launched Phase III for linzagolix (endometriosis) in Japan
Forecast Projection:
The Global GnRH Agonists and Antagonists Drugs for Endometriosis Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Global GnRH Agonists and Antagonists Drugs for Endometriosis Market report is built on solid intelligence - powered by both primary and secondary research. Our analysts have deep-dived into every factor that can influence your business roadmap, including government regulations, competitive landscape, tech innovations, historical market behavior, upcoming breakthroughs, adjacent industry trends, market volatility, growth prospects, and potential risks.
Government Regulations
UK's Medicines (GnRH Analogues) Order 2024 (effective Jan 2025) prohibits private sales/supply of GnRH agonists/antagonists for puberty suppression in under-18s unless NHS-prescribed by UK practitioners; clinical trials exempt. CHM recommends risk acknowledgment forms for pediatric use.
Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports): https://www.datamintelligence.com/buy-now-page?report=gnrh-agonists-and-antagonists-drugs-for-endometriosis-market?kb
Key Segments:
By Drug Type: (GnRH Agonists, GnRH Antagonists)
By End-User: (Hospitals, Specialty Clinics, Others)
Regional Analysis for Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1: sets the stage by defining the full scope of the report and delivering an executive summary of key market segments across regions, product types, and applications. It provides a comprehensive snapshot of current market sizes and reveals future growth potential, offering a clear vision of how the market will evolve in the short, mid, and long term.
Chapter 2: uncovers critical insights and highlights the most impactful emerging trends shaping the GnRH Agonists and Antagonists Drugs for Endometriosis market's future - essential knowledge for investors and strategists looking to stay ahead.
Chapter 3: dives deep into the competitive landscape, delivering an in-depth analysis of GnRH Agonists and Antagonists Drugs for Endometriosis manufacturers. It covers market share dynamics, strategic developments, and the latest mergers and acquisitions that are redefining the industry.
Chapter 4: profiles the market's leading players, offering detailed views of their revenue streams, profit margins, product portfolios, and recent innovations - arming you with the intel to benchmark and strategize effectively.
Chapters 5 & 6: break down revenue performance by region and country, providing a quantitative analysis that spotlights growth hotspots, development prospects, and the unique opportunities each market offers across the globe.
Chapter 7: explores market segmentation by type, revealing the size and untapped potential of each segment - guiding you toward lucrative "blue ocean" opportunities that competitors may have overlooked.
Chapter 8: analyzes the market by application, evaluating downstream sectors with the highest growth potential and identifying promising areas for expansion and investment.
Chapter 9: maps the entire industry supply chain, tracing upstream suppliers to downstream distributors, giving you full visibility into critical business linkages and value drivers.
Chapter 10: wraps up with a powerful summary of the report's key findings and strategic takeaways, delivering the must-know insights every industry stakeholder needs to make confident, forward-looking decisions.
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/gnrh-agonists-and-antagonists-drugs-for-endometriosis-market?kb
Key Supply Chain Dynamics
1. Manufacturing Hubs: Primary production in Europe (e.g., Ferring, Ipsen), US (AbbVie, Endo), and Asia (India generics). Long-acting depot formulations (3-6 month implants) dominate 70% supply for prostate cancer/endometriosis.
2. Raw Materials: Peptide synthesis APIs from China/India; glass cartridges/vials impacted by US tariffs (spring 2025), causing shortages/delays for generics/biotechs.
3. Logistics: Cold chain critical for lyophilized powders; post-COVID stockpiling mitigates disruptions, but oncology/IVF demand strains capacity.
Disruptions & Challenges
1. Shortages: Leuprolide acetate (Lupron/Eligard) ongoing US shortage (ASHP); degarelix (Firmagon) intermittent due to single-source manufacturing.
2. Tariffs/Trade: US tariffs hit APIs, glass, lab equipment; generics/biotechs reduce low-margin production; API shift to India/Europe.
3. Pandemic Legacy: Supply chain bottlenecks persist for specialized reagents; telemedicine shifts reduce clinic stock needs.
Demand Pressures
1. Prostate cancer (60% market): Aging populations, rising diagnoses drive agonists (leuprolide/triptorelin).
2. Gynecology/ART: IVF boom (endometriosis/PCOS) favors antagonists (ganirelix/cetrorelix) for rapid suppression sans flare.
3. Growth: $1.57B (2024) → $1.73B (2025) → $2.49B (2029); antagonists gaining share.
Mitigation Strategies
1. Diversification: India/Europe API expansion; inventory stockpiles; trade exemptions sought for essential meds.
2. Innovation: Oral antagonists (relugolix/Orgovyx) reduce depot reliance; biosimilars entering EU/US.
3. Regulatory: UK private pediatric supply ban (Jan 2025) shifts to NHS; clinical trials exempt.
Have Detailed Enquiry of This Report @ https://www.datamintelligence.com/enquiry/gnrh-agonists-and-antagonists-drugs-for-endometriosis-market?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States GnRH Agonists and Antagonists Drugs for Endometriosis Market to hit US$ 2,079.94 million by 2031 | Top Companies - TerSera Therapeutics LLC, Takeda Pharmaceutical Company Limited, Cipla, Lupin here
News-ID: 4298058 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Application-Specific Integrated Circuit (ASIC) Market Set for Steady Growth to U …
The Global Application-Specific Integrated Circuit (ASIC) Market reached US$ 15.7 billion in 2022 and is expected to reach US$ 34.5 billion by 2030, growing with a CAGR of 8.3% during the forecast period 2023-2030. This sustained growth is driven by the explosive demand for high-performance, energy-efficient silicon for artificial intelligence (AI) inferencing, cryptocurrency mining, and advanced wireless communication (5G/6G), coupled with the increasing need for customized acceleration solutions across automotive,…
Asthma and COPD Drug Market to Witness Steady Growth, Fueled by Innovation and H …
The Global Asthma and COPD Drug Market is expected to grow at a CAGR of 3.9% during the forecast period (2024-2031). This steady growth is propelled by the persistently high and rising global prevalence of chronic respiratory diseases, continuous innovation in biologic therapies and smart inhaler technologies, and the expanding aging population more susceptible to COPD, driving long-term treatment demand.
Get a Free Sample PDF Of This Report (Get Higher Priority…
Ambulatory Blood Pressure Monitors Market Set for Strong Growth to USD 3.42 Bill …
The Global Ambulatory Blood Pressure Monitors (ABPM) Market reached US$ 1.33 billion in 2024 and is expected to reach US$ 3.42 billion by 2033, growing at a CAGR of 11.2% during the forecast period 2025-2033. This robust growth is propelled by the rising global prevalence of hypertension, the increasing clinical preference for 24-hour ABPM over clinic readings for accurate diagnosis and treatment monitoring, and technological advancements that enhance device connectivity…
Advanced Wound Care Market Poised for Steady Growth, Driven by Rising Chronic Wo …
The Global Advanced Wound Care Market was valued at USD 10,318.90 million in 2021 and is forecast to grow at a CAGR of 4.90% during the forecast period (2024-2031). This steady growth is fueled by the increasing global prevalence of chronic wounds, such as diabetic foot ulcers and venous leg ulcers, the aging global population, and continuous advancements in wound therapy technologies that improve healing times and patient outcomes.
Get a…
More Releases for GnRH
Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market to Record 8.5% …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market Outlook: How is the Market Expected to Grow by 2025?
The market size of gonadotropin-releasing hormone (GnRH) receptor antagonists has experienced significant growth in recent times. Predictions indicate a rise from $1.46 billion in 2024 to $1.59 billion in 2025, with an 8.8% compound…
Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Industry Gr …
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
What Is the Long-Term Growth Forecast for the Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Size 2025?
The market for gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs has seen considerable growth in recent past. The size of the market is expected to increase from $1.57 billion in 2024 to $1.73 billion…
Gonadotropin-Releasing Hormone (GnRH) Agonist Market Growth Accelerates: Strateg …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Gonadotropin-Releasing Hormone (GnRH) Agonist Industry Market Size Be by 2025?
The market size of the gonadotropin-releasing hormone (GnRH) agonist has been experiencing consistent growth in the last few years. It's projected to escalate from $4.1 billion in 2024 to $4.23 billion in 2025, with a compound…
GnRH Receptor Antagonists Market to Hit USD 1.2 billion in 2024, Highlighting St …
New Jersey, US State: "The global GnRH Receptor Antagonists market in the Healthcare and Pharmaceuticals category is projected to reach USD 2.5 billion by 2031, growing at a CAGR of 9.5% from 2025 to 2031. With rising industrial adoption and continuous innovation in Healthcare and Pharmaceuticals applications, the market is estimated to hit USD 1.2 billion in 2024, highlighting strong growth potential throughout the forecast period."
GnRH Receptor Antagonists Market Size…
Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market to Reach $4.72 Billi …
What Is the Expected Size and Growth Rate of the Gonadotropin-Releasing Hormone (GnRH) Agonist Market?
There has been a consistent expansion in the market size of the gonadotropin-releasing hormone (GnRH) agonist in the past few years. The market is projected to rise from $4.1 billion in 2024 to $4.23 billion in 2025 with a compound annual growth rate (CAGR) of 3.2%. This surge during the historical period can be credited to…
GnRH Agonists & Antagonists Drugs for Endometriosis Market Rapid Growth: Size, F …
The GnRH Agonists & Antagonists Drugs for Endometriosis Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Get a Free Sample PDF - https://datamintelligence.com/download-sample/gnrh-agonists-and-antagonists-drugs-market
The Global GnRH agonists and antagonists drugs for…
